Effects of Triterpenoid-Rich Extracts of *Ganoderma tsugae* on Airway Hyperreactivity and Th2 Responses in vivo

Miaw-Ling Chen  Bi-Fong Lin

Department of Biochemical Science and Technology, Institute of Microbiology and Biochemistry, College of Life Science, National Taiwan University, Taipei, Taiwan, ROC

Abstract

**Background:** Airway inflammation and Th2 responses play central roles in allergic asthma. We have previously reported that *Ganoderma tsugae* supplementation could attenuate airway inflammation in the murine model. Since it remains unclear which part of the *G. tsugae* exerts this effect on allergic asthma in vivo, this study was meant to investigate if triterpenoid extracts have anti-inflammatory effects on airway responses and regulatory effects on Th2 responses.

**Methods:** BALB/c mice sensitized intraperitoneally and challenged with ovalbumin (OVA) were treated with either triterpenoid-rich extracts (TRE) of *G. tsugae* or prednisolone for 2 weeks. The effects of TRE on bronchial airway hyperresponsiveness (AHR), airway inflammation, serum antigen-specific antibody levels, and cytokine secretions from splenocytes were evaluated.

**Results:** TRE supplementation significantly decreased AHR and reduced the total infiltrating leukocytes and eosinophils, as well as the levels of inflammatory mediators, such as interleukin (IL)-4, IL-5 and eotaxin in bronchoalveolar lavage fluid when compared with those of the control group. Lung histology also showed less cell recruitment and lung damage. TRE supplements suppressed IL-5 secretions from OVA-stimulated splenocytes, but did not affect the cell number of splenocytes, which was also reduced by prednisolone. Although OVA-specific immunoglobulin E levels were not significantly different among the groups, a lower level of OVA-specific immunoglobulin G1, another Th2-related antibody, was found in TRE and prednisolone treatment.

**Conclusions:** TRE of *G. tsugae* exert anti-inflammatory effects on airway responses and attenuate Th2 responses without the overall immunosuppression effects in allergic murine models of asthma.

Introduction

Bronchial asthma is a chronic inflammatory disease with many clinical phenotypes. The characteristics of allergic asthma include airway hyperresponsiveness (AHR) and bronchial inflammation through the accumulation of eosinophils, lymphocytes and mast cells in the airway. Murine models of allergic bronchial asthma have been developed to study the pathophysiology of the disease. Mice sensitized and challenged with OVA significantly increase airway inflammation and Th2 responses [1]. The allergic immune responses in asthma arise from an
imbalance between Th1 and Th2 cells, and asthmatic inflammation is clearly associated with an increase in Th2 cytokines interleukin (IL)-4, IL-13 and IL-5, which play essential roles in both immunoglobulin (Ig) E production and eosinophilic infiltration [2].

Several studies have suggested that a Chinese herbal formula decreases airway inflammation and antigen-specific IgE levels, as well as modulating Th1/Th2 responses [3–5]. Moreover, all of the proposed herbal formulas contain some amount of *Ganoderma*, which have been reported to possess both antitumor and immunomodulatory effects [6].

*Ganoderma lucidum* is the most studied species of the *Ganoderma*. It is known for many biological activities due to its polysaccharides, oxygenated triterpenoids, and LZ-8 of *Ganoderma* [6]. *Ganoderma tsugae* is another commonly used species in Chinese herbal medicine and health food. It has attracted much attention because its polysaccharides have been demonstrated to have antitumor activity [7, 8]. In our previous studies, the *G. tsugae* extract increased IL-2 and decreased IL-4 cytokine production from splenocytes of BALB/c mice [9]. Further studies showed that the *G. tsugae* extract alleviated inflammatory mediator secretion in bronchoalveolar lavage fluid (BALF) of airway-sensitized and challenged BALB/c mice [1].

It has also been reported that triterpenoids decrease histamine release from rat peritoneal mast cells [10]. More than 100 species of triterpenoids have been isolated from *Ganoderma*. Therefore, to investigate if triterpenoids are the effective component, a triterpenoid-rich fraction of *G. tsugae* was applied to treat airway-sensitized and challenged BALB/c mice in this study. We report here for the first time that triterpenoid-rich extracts (TRE) of *Ganoderma* attenuate allergen-induced airway inflammation and Th2 responses in vivo.

### Materials and Methods

#### Materials

The TRE were provided by the Double Crane Group (Yung-Kien Industry Corp., Taiwan). The TRE fraction was 4.2%, extracted from the fruiting body of *G. tsugae* YK-01 with acidic ethyl acetate, as previously described [11]. The purity of the TRE was identified by reverse-phase HPLC methods to be 38% and contained nine major peaks identified as ganoderic acids (ganoderic acids A, B, C, C5, C6, D, E and G, and ganoderenic acid D), reported previously by Chen and Chen [12].

#### Animal and Experimental Protocol

Inbred female BALB/c mice (6 weeks old) were purchased from the Animal Center at the National Taiwan University College of Medicine, Taipei, Taiwan, and maintained at the Department of Biochemical Science and Technology at the National Taiwan University. The animal room was kept on a 12-hour light and 12-hour dark cycle at constant temperature (25 ± 2°C) and humidity. The mice were housed individually in stainless steel wire cages and fed on a chow diet (Lab Rodent Chow 5001; Ralson Purina, St. Louis, Mo., USA) to acclimatize for 2 weeks before feeding the experimental diet.

The BALB/c mice (8 weeks old) were sensitized and challenged to induce allergic airway inflammation (fig. 1). In brief, mice were sensitized intraperitoneally with ovalbumins (OVA; Sigma, St. Louis, Mo., USA) in alum adjuvant (Imject® Alum; Pierce, Rockford, Ill., USA) three times twice weekly according to our previous study [13]. Nonsensitized control mice received alum only for confirmation of sensitization operation (data not shown). Then, these OVA-sensitized mice were divided by randomization of OVA-specific IgE titers into five groups (n = 10), including a control group, three experimental groups which were fed with 1, 2
and 5 mg/day TRE of G. tsugae, respectively, and a positive control treated with prednisolone, a steroid anti-inflammatory drug (5 mg/kg body weight; Sigma). During 2 weeks of treatment, OVA-sensitized BALB/c mice were then challenged twice at 3-day intervals by aerosolized OVA at a concentration of 5% OVA in phosphate-buffered saline (PBS) for 30 min in a chamber equipped with an ultrasonic nebulizer (Ultra-Neb99; DeVilbiss, Somerset, Pa., USA). Nonsensitized control mice received PBS only. AHR was measured the next day after the second challenge. One week later, the mice received a third challenge and were euthanized by CO₂ inhalation. BALF was collected and assayed. Serum and spleen cells were also collected for further analysis of the immune responses.

**Determination of AHR**

An increase in AHR after methacholine (Sigma) challenge has been demonstrated as a diagnostic sign of asthma in animal models [14]. Twenty-four hours after the secondary OVA inhalation, AHR was measured in mice using whole-body plethysmography (Buxco, Wilmington, N.C., USA). Airway responsiveness was measured by aerosolizing increasing concentrations of methacholine 1.25–50 mg/ml in PBS, using an AeroSonic ultrasonic nebulizer (DeVilbiss). After each concentration, recordings were taken for 3 min. The enhanced pause (Penh) values measured during each 3-min sequence were expressed as an increase over baseline Penh values following PBS exposure.

**Collection of BALF and Cellular Differential Counts**

BALF collection and differential cell counts were manipulated as described by Lin et al. [1]. Briefly, after the mice were euthanized by CO₂ inhalation and intubated, their lungs and airways were lavaged with 5 instillations of 0.5 ml sterile saline (0.9% NaCl) for a total of 2.5 ml through the trachea. Approximately 2.5 ml of BALF was recovered with each sample and the volume did not differ significantly among groups. BALF was centrifuged at 200 g for 10 min at 4°C. The supernatant was collected and kept at –80°C for IL-4, IL-5, eotaxin and prostaglandin E₂ (PGE₂) analysis. The cell pellet was washed and resuspended in 250 μl normal saline containing 10% bovine serum albumin (BSA; Sigma). Total cells were counted with a hemocytometer using the trypsin blue dye exclusion method. BALF cells with a concentration of 2 × 10⁶ were cyt centrifuged and then stained with Liu’s stain for eosinophil, neutrophil, macrophage and lymphocyte counts. According to the standard morphologic criteria, at least 200 white blood cells were counted, and the total number of each cell type from BALF was calculated.

**Lung Histology**

To evaluate the effects of TRE on lung inflammation, after the lavage, the lungs of mice were immediately removed and fixed in 10% neutral buffered formalin. The lung tissues were subsequently embedded in paraffin and cut into 5-μm-thick sections. The frozen sections were stained with hematoxylin-eosin, and microscopic images were made with a Leica DMR system (Leica Camera AG, Solms, Germany).

**Cytokines and Chemokine Assay of BALF and Splenocytes**

Splenocytes with a concentration of 5 × 10⁶ cells/ml were set up in 48-well plates in RPMI-1640 medium supplemented with tissue culture medium in the absence or presence of mitogen, such as concavalin A (ConA, 5 μg/ml; Sigma) or OVA (25 μg/ml; Sigma) for 48 h. The cytokine levels in BALF and splenocyte culture supernatants were measured by sandwich ELISA methods [1]. Briefly, the anti-cytokine antibody, including purified rat anti-mouse cytokine monoclonal antibodies IL-2, interferon (IFN)-γ, IL-4 and IL-5 (Pharmingen, San Diego, Calif., USA), was coated in the 96-well plates (Nunc, Roskilde, Denmark). After overnight incubation at 4°C and having been blocked with PBS containing 1% BSA for 30 min, the samples and standards (recombinant mouse cytokines; Pharmingen) were added to the 96-well plates for 2 h of incubation. The biotin-conjugated antibodies (biotinylated anti-mouse cytokine monoclonal antibodies; Pharmingen) were added and incubated. After washing, the streptavidin-conjugated peroxidase (Pierce) was added for 1 h. The substrates, 2,2′-azino-bis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS; Sigma), were added to each well for 20 min to develop color. The plates were read in a microplate autoreader (Microplate autoreader; Bio-Tek Instrument, Inc., Winooski, Vt., USA) at 405 nm. The detection limits for IL-2, IFN-γ and IL-5 are 75 pg/ml, and 3.9 pg/ml for IL-4.

The eotaxin concentration in BALF was determined by mouse eotaxin sandwich ELISA kit (R&D Systems, Minneapolis, Minn., USA). The eotaxin concentration was assayed according to the manufacturer’s instructions. After the color reagent was added, the plate was incubated at room temperature for 20 min for color development. The absorbance in the microplate was measured at 630 nm on a plate reader. The eotaxin level in BALF was determined using the standard curve. The detection limit for eotaxin is 3.9 pg/ml.

**Determination of PGE₂ Levels in BALF**

The PGE₂ level in BALF was determined by the competitive enzyme immunoassay kit (PGE₂ Enzyme Immunoassay kit; Assay Designs, Inc., Ann Arbor, Mich., USA). A monoclonal antibody to PGE₂ supplied in the kit was used to bind, in a competitive manner, PGE₂ in the sample or PGE₂ which conjugated with an alkaline phosphatase molecule. After a simultaneous incubation at room temperature, the excess reagents were washed away and the substrate was added. After a sufficient incubation time, the enzyme reaction was stopped and the yellow color generated was read on a microplate reader at 405 nm. Using the standard curve, the PGE₂ concentration for each unknown sample was determined. The detection limit for PGE₂ is 39 pg/ml.

**Determination of Anti-OVA Antibodies**

Serum anti-OVA IgE, IgG1 and IgG2a antibody titers were measured by the ELISA method, as previously described [13]. Briefly, 96-well plates were coated with 10 μg OVA/ml NaHCO₃ buffer (0.1 M, pH 8.2). After overnight incubation at 4°C and having been blocked with 1% BSA/PBS buffer for 2 h at room temperature, the serum samples and positive control serum were appropriately diluted with blocking buffer (1/50 for IgE, 1/500,000 for IgG1, and 1/800 for IgG2a assay, respectively) and added to the 96-well plate. After 2 h incubation, the plates were washed and biotin-conjugated anti-mouse IgG1, IgG2a and IgE (Pharmingen) were added. After further 2 h incubation, streptavidin-conjugated peroxidases were likewise added. The enzyme substrate ABTS was added and incubated for 20 min at room temperature. The antibody levels of the samples were compared with the positive sample. The positive sample was a pool of serum collected from...
OVA-sensitized mice with strong response (optical density $>1$). The results of the antibody titer were expressed as ELISA units (EU): \( EU = \frac{(A_{\text{sample}} - A_{\text{blank}})}{(A_{\text{positive}} - A_{\text{blank}})} \).

**Statistical Analysis**

The significance of difference among all of the groups was analyzed statistically by unpaired Student’s t test of the SAS program system (Statistical Application Software, SAS Windows version 8.2; SAS Institute Inc., Cary, N.C., USA) throughout the study. Data are expressed as mean ± SD. Differences between the control and other groups were considered statistically significantly if \( p < 0.05 \).

**Results**

**TRE Suppressed AHR and Inflammation**

Figure 2 shows AHR to aerosolized methacholine measured 24 h after the secondary 5% OVA solution pulmonary challenge. With the increase in methacholine concentration, the Penh values were increased compared with the baseline. Both TRE and prednisolone treatment significantly reduced Penh values when challenged with 50 mg/ml methacholine.

Airway inflammation is the characteristic of allergic asthma. Cell infiltration, eosinophilia and IL-4, IL-5, eotaxin and PGE$_2$ secretions in BALF are the indicators of
Effects of Ganoderma tsugae Extract on Airways

As shown in table 1, prednisolone, an anti-inflammatory drug, remarkably decreased cell infiltration in BALF. TRE supplement significantly decreased eosinophil recruitment, but had no significant effect on monocytes. The TRE 1-mg and TRE 2-mg groups also significantly decreased total cell infiltration and tended to decrease (0.05 < p < 0.1) neutrophils and lymphocyte infiltration in BALF, showing significantly lower lymphocytes in the TRE 2-mg group.

As shown in figure 3, IL-4, IL-5 and eotaxin levels in BALF were significantly reduced in all TRE and prednisolone groups. In addition, the PGE\textsubscript{2} level in BALF was lower in the TRE and prednisolone groups compared to the control group.

**Fig. 3.** Effects of triterpenoid supplementation on inflammatory mediators in BALF from OVA-sensitized and challenged BALB/c mice after 2 weeks of supplementation. BALF was collected 24 h after the last OVA inhalations. The inflammatory mediators in BALF were assayed as described in Materials and Methods, and data were expressed as the total amount in each BALF from each mouse. * p < 0.05; significantly different from the control group (Student’s t test; n = 8–10, mean ± SD).
greatly reduced by prednisolone treatment and only significantly reduced in the TRE 1-mg group. It suggests that TRE possesses a similar anti-inflammatory effect with prednisolone that is commonly used for the treatment of asthma. The lung histology shown in figure 4 indicated that under OVA sensitization and challenge, many cells infiltrated around the bronchial and lung alveoli in the control group. However, less inflammatory cell infiltration in the lungs from the TRE and prednisolone treatment groups was noted.

**Effects of TRE on Splenocyte Numbers and Th2 Cell Responses**

As shown in table 2, total splenocytes were not significantly affected by TRE supplement, but were significantly reduced in the prednisolone compared with the control group. However, secretion of IL-5, one of the Th2 cytokines, from OVA-stimulated splenocytes was significantly lower by both TRE and prednisolone treatment (table 2). Another Th2 cytokine, IL-4, also tended to be lower ($0.05 < p < 0.1$) in the TRE 1-mg and prednisolone groups.
groups. Secretion of Th1 cytokine, IL-2 and IFN-γ was not significantly affected by TRE treatment (data not shown). The spontaneous cytokine secretion was almost undetectable in this study. Prednisolone treatment significantly decreased OVA-stimulated IFN-γ and ConA-stimulated IL-2 production, which was not affected by TRE supplement (data not shown).

Effects of TRE on OVA-Specific Antibodies

Serum OVA-specific IgE, IgG1 and IgG2a antibody levels are shown in Table 3. The OVA-specific IgE titers were not significantly decreased by TRE and prednisolone treatment for 7 days, at day 49 of the experimental procedure. OVA-specific IgG1 levels were significantly lower in the TRE 1-mg, TRE 5-mg and prednisolone groups. The IgG2a levels were also decreased by prednisolone treatment, but not by TRE treatment.

Discussion

It has been demonstrated that triterpenoid extracts from G. lucidum decrease histamine release from rat peritoneal mast cells in vitro [10]. Our report is the first study on the effect of triterpenoid extract of G. tsugae on allergic asthma in vivo. Mice were sensitized and challenged with OVA to induce the typical asthmatic symptoms, such as AHR and eosinophilic airway inflammation. Steroids, such as prednisolone, shown to reduce eosinophilia that was induced by IL-5 challenge in the airway of Brown Norway rats [15], was used as the positive therapeutic reagent to evaluate the effect on allergic immune responses by dietary treatment.

In this study, prednisolone treatment significantly decreased AHR and the inflammatory mediators, such as IL-4, IL-5, PGE2 and eotaxin secretion. Similarly, TRE treatment also decreased AHR, cell recruitment in BALF and the lung, and inflammatory mediators, IL-4, IL-5 and eotaxin in BALF, which alleviate allergic airway inflammation. Several reports have suggested that IL-5 and eotaxin both play essential roles in the recruitment of eosinophils to the inflammatory sites [16, 17]. Also, IL-4 plays a role in the induction of endothelial vascular cell adhesion molecule-1 expression, which leads to preferential eosinophil recruitment [18]. Blockade of IL-4 receptor or lack of IL-4 receptor α chain significantly reduced AHR induced by antigen sensitization, suggesting that the IL-4 receptor is necessary for in vivo development of antigen-induced AHR [19, 20]. We also found that BALF eosinophilia significantly correlated with the amounts of IL-5 (r = 0.61) and eotaxin (r = 0.70) in BALF, and IL-4 production in BALF significantly correlated with AHR (r = 0.33) in this study. Our results indicated that the triterpenoids of G. tsugae might alleviate AHR via reducing IL-4, eotaxin and IL-5 levels in BALF, thus decreasing eosinophilic infiltration in the airway.

Although some studies showed that an amplified AHR response was not directly correlated with the recruitment

![Image](https://example.com/image.png)

Table 2. Effects of triterpenoid supplementation on splenocyte counts and cytokine secretion by OVA-stimulated splenocytes of OVA-sensitized and challenged BALB/c mice after 2 weeks of feeding

<table>
<thead>
<tr>
<th>Groups</th>
<th>Total splenocytes, × 10⁷</th>
<th>Th2 cytokine, pg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>IL-4</td>
</tr>
<tr>
<td>Control</td>
<td>4.57 ± 1.76</td>
<td>12.50 ± 1.82</td>
</tr>
<tr>
<td>TRE 1 mg</td>
<td>4.72 ± 2.55</td>
<td>9.90 ± 3.25**</td>
</tr>
<tr>
<td>TRE 2 mg</td>
<td>5.29 ± 2.51</td>
<td>13.48 ± 3.02</td>
</tr>
<tr>
<td>TRE 5 mg</td>
<td>5.30 ± 2.76</td>
<td>10.43 ± 3.72</td>
</tr>
<tr>
<td>Prednisolone</td>
<td>0.75 ± 0.53*</td>
<td>9.18 ± 2.13**</td>
</tr>
</tbody>
</table>

The 5 × 10⁶ cells/ml splenocytes were cultured with the medium described earlier in the absence or presence of OVA (25 μg/ml) for 48 h. IL-4 and IL-5 levels were determined by the ELISA method.

* p < 0.05; ** 0.05 < p < 0.1; significantly different from the control group (log-transformed data analyzed by Student’s t test; n = 8–10, mean ± SD).

Table 3. Effects of triterpenoid supplementation on serum OVA-specific antibody levels of OVA-sensitized and challenged BALB/c mice after 2 weeks of feeding

<table>
<thead>
<tr>
<th>OVA-specific antibody titer, ELISA units</th>
<th>IgE</th>
<th>IgG1</th>
<th>IgG2a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.51 ± 0.24</td>
<td>1.29 ± 0.36</td>
<td>1.10 ± 0.59</td>
</tr>
<tr>
<td>TRE 1 mg</td>
<td>0.39 ± 0.10</td>
<td>0.98 ± 0.38*</td>
<td>1.19 ± 0.59</td>
</tr>
<tr>
<td>TRE 2 mg</td>
<td>0.49 ± 0.15</td>
<td>1.07 ± 0.25</td>
<td>1.60 ± 0.72</td>
</tr>
<tr>
<td>TRE 5 mg</td>
<td>0.49 ± 0.19</td>
<td>0.98 ± 0.39*</td>
<td>1.06 ± 0.74</td>
</tr>
<tr>
<td>Prednisolone</td>
<td>0.40 ± 0.14</td>
<td>0.61 ± 0.17*</td>
<td>0.63 ± 0.39**</td>
</tr>
</tbody>
</table>

Sera were collected for antibody analysis on day 49. OVA-specific IgE, IgG1 and IgG2a levels were determined by ELISA.

* p < 0.05; significantly different from the control group (n = 8–10, mean ± SD).

** Significantly different from the control group by log-transformed data.

![Image](https://example.com/image.png)
of eosinophils in eosinophil-deficient mice or in several cytokine-deficient mice administered with IL-13 [21, 20], the researchers still suggested a close relationship between eosinophils, IL-5 and IL-13 in the mechanisms causing AHR in the allergic lung, and also the contribution of eosinophils in subepithelial collagen deposition and the increases in airway smooth muscle. Despite that the contribution of eosinophils to lung dysfunction has been controversial, the eosinophil is thought to be the critical cell involved in asthma pathogenesis. MacKenzie et al. [22] have demonstrated that eosinophils modulate allergic inflammation by amplifying Th2 cell responses. In addition, it has been reported that epithelial damage of the trachea is associated with mobilization of neutrophils or eosinophils in the airway lumen during acute exacerbations of asthma [23]. The number of airway neutrophils increases during the late-phase response after an allergen challenge [24]. Neutrophils are also a potential source of inflammatory mediators in allergic asthma [25]. Our data demonstrated decreased eosinophils and neutrophil infiltration in BALF, especially eosinophilia, of TRE-supplemented groups (table 1). Consistently, lung histology also showed less inflammatory cell infiltration in the lungs of TRE-supplemented mice (fig. 4). Our data demonstrated that triterpenoid supplementation should suppress cellular inflammation in allergic asthma.

In addition, eicosanoids have been linked with inflammatory diseases, such as cardiovascular disease and asthma [26]. An increased PGE2 level was demonstrated to aggravate the inflammatory process [27]. In the present study, prednisolone, an anti-inflammatory drug, dramatically decreased PGE2 production in BALF of OVA-sensitized and challenged mice. PGE2 levels were lower in BALF of TRE-supplemented mice, though only the low-dose group (1 mg/day) reached a statistical significance. PGE2 inhibits the production of Th1 cytokines but not of Th2 cytokines [28]. It has been reported that PGE2 inhibited IL-12 synthesis, which is a critical cytokine in Th1 development [29]. T cell responses in allergic asthma are known to be Th2 cell dominant. Th2 cell cytokines, such as IL-4 and IL-5, have been reported to play crucial roles in the late phase of allergic disease [30]. Hence, blocking Th2-derived responses or increasing the function of Th1 cells can be regarded as an important target for the treatments of allergic asthma. A recent report showed that the Chinese herbal medicine FAHF-2, a G. lucidum-rich formula, suppressed IL-4, IL-5 and IL-13 production from antigen-stimulated splenocytes [5]. Our data demonstrated that IL-4 and IL-5 levels significantly decreased in BALF of TRE-supplemented and prednisolone groups. Further, the effect on splenocytes by TRE supplement was also investigated. The secretions of Th1 cytokines, such as IL-2 and IFN-γ, from OVA-stimulated splenocytes were not significantly affected by TRE supplement, but suppressed by prednisolone (data not shown). However, the secretion of one of the Th2 cytokines, IL-5, was significantly lower in TRE- or prednisolone-treated mice. Another Th2 cytokine, IL-4, only tended to be lower in the TRE 1-mg and prednisolone groups (0.05 < p < 0.1). Cytokines such as IL-5 derived from Th2 cells were found to induce eosinophilia, which is critical in the late stage of inflammation of asthma [31]. Therefore, suppression of IL-5 secretion by splenocytes might contribute to less eosinophil infiltration and lower levels of inflammatory mediators in BALF and lung tissue in the present study.

Both in vivo and in vitro evidence suggested that cytokines like IL-4 are important for the immunoglobulin class switch from IgM to IgE [32, 33]. Antigen-specific IgE is essential for the development of allergic reactions. It starts the cascade of allergic responses through cross-linking with antigens. Several therapies have been designed to reduce the amount or effect of IgE, and blocking the binding of IgE to its receptors is the most effective strategy for allergic diseases [34]. In the present study, the OVA-specific IgE levels were not significantly lower in the TRE and prednisolone groups. It might be explained by the suppression of OVA-stimulated IL-4 secretion from splenocytes of OVA-sensitized and challenged mice which was not intense enough to decrease IgE significantly, though Th2-related antigen-specific IgG1 antibody levels were significantly lower in the TRE 1-mg, TRE 5-mg and prednisolone groups. Antigen-specific IgG1 also plays a critical role in allergic responses. In addition to the activation of mast cells by IgE binding via the FceRI receptor, which initiates allergic response, antigen-specific IgG1 may also activate mast cells through the binding of the FcyRIII receptor on the surface of murine mast cells [35]. It has been demonstrated that IgG1 increased AHR after airway challenge [36]. One study also showed that Dermatophagoides pteronyssinus group 2 specific IgG1 was significantly decreased while IgG2a production was increased in D. pteronyssinus group 2 intraperitoneally sensitized mice fed with G. lucidum [37]. Therefore, the IgG1 lowering effect of Ganoderma may be beneficial in antigen-specific allergic responses.

Corticosteroids are the most common and powerful anti-inflammatory drugs used to treat asthma for a long time. Prednisolone treatment is known to decrease AHR, eosinophilia in the lung, serum IgE levels, and IL-2 and IL-4 production by ConA-stimulated splenocytes [38,
39]. However, the side effects of corticosteroids may cause problems. In the present study, prednisolone treatment significantly decreased the relative spleen and lung weight of allergic mice, but TRE did not (data not shown). Prednisolone did not only suppress Th2 responses but also total immune cell population, Th1 responses, such as IL-2 and IFN-γ secretions by OVA- and ConA-stimulated splenocytes (data not shown), and OVA-specific IgG2a production. These might be due to the induction of T cell apoptosis by corticosteroids [40]. Unlike prednisolone, TRE did not affect or decrease spleen cell numbers. It has been known that the mechanisms of prednisolone treatment for allergic asthma suppress immune responses, which might pose a risk of infection. The TRE supplement decreased airway inflammation and Th2 responses, but did not suppress Th1 responses in this study. In addition, the suppressive effect of TRE was dose independent, which was inconsistent with the previous study when a whole extract of fruit bodies of G. tsugae was tested [1].

In conclusion, Th2 responses such as IL-5 secreted from OVA-stimulated splenocytes, serum OVA-specific IgG1 levels, eosinophil infiltration and secretions of IL-4, IL-5 and eotaxin in BALF, and thus AHR, were significantly suppressed in OVA-sensitized and challenged mice supplemented with TRE of G. tsugae. These results suggest that triterpenoids may have possible therapeutic applications in allergic asthma. The mechanism of triterpenoids of G. tsugae in regulation of cytokine production is the subject of ongoing research.

References

1. Lin JY, Chen ML, Chiang BL, Lin BF: Gano
2. O’Byrne PM, Inman MD, Adelroth E: Reas-
5. Srivastava K, Kattan JD, Zou ZM, Li JH, Zhang L, Wallenstein S, Goldfarb J, Sampson HA, Li XM: The Chinese herbal medi-
6. Shiao MS: Natural products of the medicinal fungus Ganoderma lucidum: occurrence, bi-
mor active polysaccharides from the Chi-
nese mushroom Songshan lingzhi, the fruit-
8. Peng Y, Zhang L, Zeng F, Kennedy JF: Struc-
ture and antitumor activities of the water-
9. Chen ML, Lin JY, Lin BF: The immunomodula-
cally active constituents of Ganoderma lu-
cidum (Fr) Karst. Histamine release-inhibi-
11. Chen DH, Shiuo WY, Wang KC, Huang SY, Shiie YT, Tsai CM, Shie JF, Chen KD: Chemoe-
14. Hamelmann E, Schwarze J, Takeda K, Os-
hiba A, Larsen GL, Irvin GG, Gelfand EW: Noninvasive measurement of airway respon-
15. Takizawa T, Kawaka N, Tanaka H, Nagai H: Effect of antiallergic drugs on interleukin 5-
induced eosinophil infiltration of rat air-
16. Menzies-Gow A, Ying S, Sabroe I, Stubbs VL, Soder D, Williams TJ, Kay AB: Eotaxin (CCL11) and eotaxin-2 (CCL24) induce re-
cruitment of eosinophils, basophils, neutro-
phils, and macrophages as well as features of early- and late-phase allergic reactions fol-
17. Lampinen M, Rak S, Venge P: The role of inter-
20. Yang M, Hogan SP, Henry PJ, Matthaei KI, McKenzie AN, Young IG, Rothenberg ME, Foster PS: Interleukin-13 mediates airways hyperreactivity through the IL-4 receptor-
21. Humbles AA, Lloyd CM, McMillan SJ, Friend DS, Xanthou G, McKenna EE, Ghir-
an S, Gerard NP, Yu C, Orkin SH, Gerard C: A critical role for eosinophils in allergic air-


35 Miyajima I, Dombrowicz D, Martin TR, Ravetch JV, Kinet JP, Galli SJ: Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and FcyRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis. J Clin Invest 1997;99:901–914.


